IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immunome Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$16.77+0.30 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.90B
- P/E (TTM)
- –
- Dividend yield
- –
Immunome Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Immunome's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.